JP2014526462A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526462A5
JP2014526462A5 JP2014529643A JP2014529643A JP2014526462A5 JP 2014526462 A5 JP2014526462 A5 JP 2014526462A5 JP 2014529643 A JP2014529643 A JP 2014529643A JP 2014529643 A JP2014529643 A JP 2014529643A JP 2014526462 A5 JP2014526462 A5 JP 2014526462A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
oncoprotein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014529643A
Other languages
English (en)
Japanese (ja)
Other versions
JP6153526B2 (ja
JP2014526462A (ja
Filing date
Publication date
Priority claimed from SG2012011581A external-priority patent/SG193038A1/en
Application filed filed Critical
Priority claimed from PCT/SG2012/000305 external-priority patent/WO2013036201A1/en
Publication of JP2014526462A publication Critical patent/JP2014526462A/ja
Publication of JP2014526462A5 publication Critical patent/JP2014526462A5/ja
Application granted granted Critical
Publication of JP6153526B2 publication Critical patent/JP6153526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014529643A 2011-09-06 2012-08-29 ポリペプチドワクチン Active JP6153526B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161531290P 2011-09-06 2011-09-06
US61/531,290 2011-09-06
SG2012011581A SG193038A1 (en) 2012-02-17 2012-02-17 Polypeptide vaccine
SG201201158-1 2012-02-17
SG2012046447 2012-06-21
SG201204644-7 2012-06-21
PCT/SG2012/000305 WO2013036201A1 (en) 2011-09-06 2012-08-29 Polypeptide vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017106379A Division JP6676584B2 (ja) 2011-09-06 2017-05-30 ポリペプチドワクチン

Publications (3)

Publication Number Publication Date
JP2014526462A JP2014526462A (ja) 2014-10-06
JP2014526462A5 true JP2014526462A5 (enExample) 2015-08-27
JP6153526B2 JP6153526B2 (ja) 2017-06-28

Family

ID=54259018

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014529643A Active JP6153526B2 (ja) 2011-09-06 2012-08-29 ポリペプチドワクチン
JP2017106379A Active JP6676584B2 (ja) 2011-09-06 2017-05-30 ポリペプチドワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017106379A Active JP6676584B2 (ja) 2011-09-06 2017-05-30 ポリペプチドワクチン

Country Status (6)

Country Link
US (2) US10258676B2 (enExample)
EP (1) EP2753345B1 (enExample)
JP (2) JP6153526B2 (enExample)
CN (2) CN103987396A (enExample)
SG (2) SG11201400432VA (enExample)
WO (1) WO2013036201A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2533806B1 (en) 2010-02-10 2019-09-04 Mayo Foundation for Medical Education and Research Methods and materials for treating cancer
US20140005119A1 (en) * 2012-06-28 2014-01-02 Case Western Reserve University COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
US20170049870A1 (en) * 2012-08-10 2017-02-23 Kanagawa Prefectural Hospital Organization Antigen Peptide Derived From the Sequence of Epidermal Growth Factor Receptor Having T790M Point Mutation
US9505824B2 (en) 2012-08-10 2016-11-29 Kanagawa Prefectural Hospital Organization Antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
EP3119426A4 (en) * 2014-03-19 2018-02-28 Mayo Foundation for Medical Education and Research Methods and materials for treating cancer
EP3119427B1 (en) 2014-03-19 2018-12-26 Mayo Foundation for Medical Education and Research Methods and materials for treating cancer
US20170196952A1 (en) * 2014-07-07 2017-07-13 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
SG10201404895XA (en) * 2014-08-13 2016-03-30 Agency Science Tech & Res Diagnosis
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
CA2986235A1 (en) * 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
CN108697779B (zh) * 2016-01-07 2023-09-19 杜克大学 癌症疫苗和递送方法
US12220451B2 (en) * 2016-02-04 2025-02-11 Duke University Cell-based vaccine compositions and methods of use
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
AU2019403393B2 (en) * 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
WO2020145222A1 (ja) * 2019-01-07 2020-07-16 地方独立行政法人神奈川県立病院機構 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
US12570696B2 (en) 2019-11-07 2026-03-10 Shenzhen Gino Biotechnology Co., Ltd. Tumor-specific polypeptide sequence and use thereof
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN111072763A (zh) * 2019-12-23 2020-04-28 维塔恩(广州)医药有限公司 肿瘤相关基因gnas突变相关抗原短肽及其应用
CN111393509B (zh) * 2020-03-30 2022-03-29 国家纳米科学中心 靶向特异性多肽及其应用
CN111285935B (zh) * 2020-05-13 2020-09-11 方达医药技术(上海)有限公司 特异性检测braf基因突变的抗体及其在制备癌症检测试剂盒中的用途
CN116157513A (zh) 2020-08-18 2023-05-23 昂希莱斯制药公司 经修饰的猪胰腺弹性蛋白酶蛋白
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
EP4337677A1 (en) * 2021-05-14 2024-03-20 Oslo University Hospital Mutated gnas peptides
CN115804834B (zh) * 2021-08-10 2025-10-21 昆明医科大学 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
JP3738395B2 (ja) * 1991-08-26 2006-01-25 エピミューン,インコーポレイティド Hla−制限型b型肝炎ウィルスのctlエピトープ
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0793501A4 (en) * 1994-12-14 2000-05-03 Scripps Research Inst IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
AU2001243196A1 (en) * 2000-02-22 2001-09-03 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
US7105642B2 (en) * 2001-08-03 2006-09-12 Cell Signalling Technology, Inc. Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
US7655751B2 (en) 2004-01-23 2010-02-02 Green Peptide Co., Ltd. Epidermal growth factor receptor-derived peptides
CA2605749C (en) * 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
DE602006006046D1 (de) * 2005-05-09 2009-05-14 Vaxon Biotech Verwendung nativer peptide und deren optimierter derivate zur impfung
WO2007110098A1 (en) * 2006-03-29 2007-10-04 Institut National De La Sante Et De La Recherche Medicale HBx PEPTIDES, CAPABLE OF ELICITING A PROMISCUOUS IMMUNODOMINANT CD4+ RESPONSE DIRECTED AGAINST HBV
WO2008008311A1 (en) 2006-07-10 2008-01-17 The Trustees Of The University Of Pennsylvania Methods for administering tumor vaccines
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
SG10201507845PA (en) * 2007-05-03 2015-10-29 Agency Science Tech & Res Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
GB2465907B (en) * 2007-08-10 2013-07-10 Agency Science Tech & Res VHZ for diagnosis and treatment of cancer
KR100995340B1 (ko) * 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 t 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
EP2331107A4 (en) 2008-08-08 2011-08-24 Agency Science Tech & Res VHZ FOR DIAGNOSIS AND TREATMENT OF TUMORS
US8524669B2 (en) 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
SG10201501561XA (en) * 2009-11-30 2015-04-29 Agency Science Tech & Res Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
EP2627671A1 (en) * 2010-10-15 2013-08-21 Université Libre de Bruxelles Estrogen receptor alpha polypeptide sequence, diagnostic and therapeutic applications thereof
CN102675422B (zh) * 2011-03-15 2014-02-05 天津托普泰克生物科技有限公司 抗乙型肝炎病毒x蛋白多肽药物
CN102675424B (zh) * 2011-03-15 2014-02-05 天津托普泰克生物科技有限公司 抗乙型肝炎病毒x蛋白多肽药物
CN102675423B (zh) * 2011-03-15 2014-02-05 天津托普泰克生物科技有限公司 抗乙型肝炎病毒x蛋白多肽药物
EP2562205A1 (de) * 2011-08-22 2013-02-27 Rhein Chemie Rheinau GmbH Neue Folien für Solarzellen
CN102357246B (zh) * 2011-11-02 2013-04-03 江苏省中医药研究院 一种egfr与her2联合多肽表位疫苗

Similar Documents

Publication Publication Date Title
HRP20200383T1 (hr) Ciljana vezna sredstva protiv b7-h1
JP2010213710A5 (enExample)
JP2020125349A5 (enExample)
JP2018517752A5 (enExample)
JP2020504716A5 (enExample)
RU2016122654A (ru) Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
JP2018536431A5 (enExample)
JP2018027952A5 (enExample)
JP2020508302A5 (enExample)
JP2015509540A5 (enExample)
JP2013064024A5 (enExample)
HRP20201681T1 (hr) Inhibitor aurora a kinaze
JP2015534975A5 (enExample)
AU2015327824A1 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
JP2018536705A5 (enExample)
JP2016500684A5 (enExample)
RU2014142057A (ru) Комплексная терапия
RU2012151571A (ru) Лекарственные препараты для лечения рака
JP2019524851A5 (enExample)
JP2025118769A5 (enExample)
RU2014141934A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями
JP2014512355A5 (enExample)
JP2015530989A5 (enExample)
JP2014532751A5 (enExample)
JP2022532430A5 (enExample)